Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate in relapsed/refractory DLBCL
NCT05563844Phase 2Active, not recruiting
- Sponsor
- Zenitar
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Zenitar. Primary endpoint: Objective Response Rate. Started Nov 2022; status: active, not recruiting.
02
Drugs
purinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05563844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563844.